摘要
探讨不同剂量重组人干扰素α2b注射液治疗小儿病毒性肺炎的临床疗效。将病毒性肺炎患儿106例随机分为高剂量组、低剂量组和对照组。三组均接受病毒性肺炎常规治疗,高剂量组和低剂量组加用重组人干扰素α2b注射液20万U/kg·次、10万U/kg·次静脉滴注,疗程1周。高剂量组、低剂量组症状改善时间短于对照组,总有效率明显高于对照组(P<0.05),高剂量组、低剂量组总有效率、住院时间无统计学差异,三组不良反应发生率无统计学差异(P>0.05)。治疗后高剂量组患儿T细胞亚群优于低剂量组患儿,低剂量组患儿T细胞亚群优于对照组患儿(P<0.05)。结果表明重组人干扰素α2b注射液可以调节患儿T细胞亚群,治疗小儿病毒性肺炎效果较好。但10万U/kg·次和20万U/kg·次临床疗效并无统计学差异。
To investigate the clinical efficacy of different doses of recombinant human interferon α2b injection in the treatment of viral pneumonia in children.106 cases of viral pneumonia in our hospital were randomly divided into high dose group,low dose group and control group.The three groups received routine treatment of viral pneumonia.High dose group and low-dose group were treated with recombinant human interferonα2 binjection at 200 thousand U/kg times and100 thousand U/kg times,respectively.The symptom improvement time of high dose group and low dose group was shorter than that of control group.The total effective rate was significantly higher than that of the control group（P〈0.05）.There was no statistical difference between the high dose group and the low dose group.There was no statistical difference between the three groups and the incidence of adverse reactions（P〉0.05）.After treatment,the T lymphocyte subsets in the high dose group were better than those in the low dose group,while the T cell subsets in the low dose group were better than those in the control group（P〈0.05）.Recombinant human interferon alpha 2b injection can regulate T cell subsets,which is effective in the treatment of viral pneumonia in children.However,there was no statistically significant difference between the 100 thousand U/kg and 200 thousand U/kg subclinical outcomes.
作者
黎小年
LI Xiao-nian(Hainan Maternity and Child Health Care Hospital, Haikou 571100, China)
出处
《医学与哲学（B）》
2018年第5期27-29,32,共4页
Medicine & Philosophy(B)
关键词
干扰素
病毒性肺炎
免疫功能
临床疗效
interferon, viral pneumonia, immune function, clinical efficacy
